Many women and physicians across the country are crying foul over the
report released today by the U.S. Preventive Services Task Force.
According to an article in the
Los Angeles Times the task force concluded "that risk of breast
cancer is very low in women age 40 to 50 and that the risk of false
positives and complications from biopsies and other invasive procedures
is too high for the procedure to be used routinely." The article draws
attention to eight "gold standard" studies which have examined how
mammography has influenced breast cancer deaths, though some say the
results are controversial.
The task force, physicians and scientists who support the findings of
the task force are urging people not to overreact to the headlines.
Many say it is merely a new way to approach mammography; that the
female standard "oh I'm forty, so I have to" and the "one size fits
all" approach is no longer valid. They're advocating that the decision
should be made by a woman and her physician. The predatory
politicians have already moved in to use the debate and the surrounding
emotions for their self-serving purposes. Meanwhile, women don't know
if they should look for the underlying conspiracy or cancel their screening appointments.
The problems lie in several pivotal areas -
1) Not all tumors are created equal and the screening does not change
the tumor.
Its very possible that many women who believed mammography
saved their lives may have lived without both the mammogram and the accompanying
treatment.
As Dr. Heidi Nelson explains in
Newsweek -
"We’ve come to a point where the ability to detect precancerous cells
has outpaced our ability to understand how these cells operate. In many
cases women are treated for breast cancer based on precancerous lumps
that are only rarely deadly. A better test for certain genetic markers
might help researchers understand which precancerous lumps are most
likely to turn into a fast-moving cancer, says Nelson, but no test
like that exists. For now, doctors treat lots of tumors that may not
kill anyone, and women are subjected to a battery of tests that don’t
provide many answers. “We can’t advise people at this stage,” says
Nelson. “We can only find things.”"
Dr. Michael Cohen of Sloan-Kettering Cancer Center in New York explains that ductal carcinoma in situ accounts for 5 to 60 percent of all tumors in women in their 40s, "It may stay there a woman's whole life and
never invade surrounding tissue, but we don't know how to tell the one that won't
spread from one that will.”
When looking at mammography and studies that indicate benefits, we have to consider
lead time
bias and
length time
bias.
My own mother died in her 59th year of breast cancer. Early on when
asked about her death, I often wanted to respond, "I'm not exactly sure
when my mother died. I only know it wasn't March 23rd." That response
certainly brought about some quizzical looks but what I really meant to
say was that the mother I knew did not die that spring morning in
1992. Although that was the day she took her last breath, the cancer
and its treatment stole her away by bits and pieces during the three
year of treatment. Since age forty, she had never missed a mammogram.
The tumor and the aggressive cells it contained appeared like magic,
a little over eleven months after her previous screening.
We've steadily improved on how to handle the side effects of radiation
and chemotherapy so retrospectively, it is difficult to say what early
screening did for her. I cannot help but wonder if her cancer was such
that it would have been better not to have known. I wonder - would it
have been better to treat the effects of metastasis palliatively once
they appeared, perhaps shortening her life but increasing its quality?
We will never know. Either way, her mammogram only served as the harbinger of her suffering and death.
2)
In order to give everyone a clearer picture of the available
information and a better chance at informed decision making, we need to
change and clarify the terms we use in reporting and describing
cancer.
The sad fact of the matter is - when we are told that early detection
saves lives we can't always be sure exactly what that means.
The term
survival rate has always infuriated me. Say that term to
most anyone and especially a newly diagnosed patient or their family
and they hear the word
cured. A ninety percent survival rate simply
means the 90 out of 100 people are still alive five years after
diagnosis. It can't tell you if 45 of those people died in years six
or that another 45 were dead by 10. It doesn't tell you if anyone in
that number is still being treated or was pronounced in remission. And
it certainly doesn't tell you anything about the measures required to
maintain that life.
The terms
disease free survival or
progression-free survival provide
only a bit more clarity. Disease-free sounds like it should mean just
what it says, but it doesn't. Disease free means achieving remission
and remission means having no signs of cancer for a period of time although it may be still
in your body. Progression-free means the individual still has cancer
but it is not getting worse. It can include those who have had some
success with treatment, but still have obvious cancer requiring aggressive treatment.
The bottom line is this - you can't make good decisions on a consumer
level, as a cancer patient or as an advocate when the terminology obscures the information you need to know.
3) We should focus in on the real target.
There's something really
cool about watching my sisters in a sea of pink solidarity, seeing the
ribbon hang from the White House or participating in a Komen event in
memory of my mother. I find meaning in that and I'm sure others do
too. Mammograms may offer us some comfort through a sense of control
and we may feel accomplished and empowered by raising awareness, but if
we spend too much energy advocating and accepting an outdated screening method we're not really sure about, we're not only being lulled - we're being sidetracked away
from the more important challenges in saving women's lives.
In the
world of detection, we need something much better than what we've been given. We need to be able to identify more aggressive forms of cancer in
its earliest stages. Most of all, in the world of tumors, we need to
better identify and understand the bad boys on a molecular level;
including the biology of stem cells, the contributing tumor environment
as well as finding more effective chemoprevention strategies.
I'm not settling for less and if you believe in the pink, neither should you.